What's Your Problem? Using Sound Waves to Destroy Tumors
8 snips
Nov 13, 2025 Mike Blue, CEO of HistoSonics, shares his fascinating journey from a garage-built ultrasound prototype to an FDA-approved cancer treatment device. He discusses how converging sound waves create bubble clouds that destroy tumors non-invasively. After a setback with a failed clinical trial, he rebranded the technology and attracted funding. Blue also reveals insights from the pivotal HOPE for Liver trial, showcasing impressive results and patient outcomes, while addressing challenges in scaling their innovative treatment for various cancers.
AI Snips
Chapters
Transcript
Episode notes
Garage Demo Sparked Big Vision
- Mike Blue first saw histotripsy in a garage demo where a bubble cloud was suspended in water.
- He immediately saw huge commercial potential and imagined selling many devices.
Reframe The Story To Win Investors
- Histosonics reframed its story from a failed prostate trial to being a non-invasive robotic surgery platform.
- That narrative shift unlocked investor interest and led to funding from surgical robotics leaders.
Build A Platform Not A One-Off
- Build a modular platform you can apply across many indications instead of a single-use device.
- Prioritize regulatory alignment to support broad soft-tissue indications for rapid expansion.